AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Forte Biosciences Inc (NASDAQ:FBRX)
17 USD
-1.175 6.465%Sponsored Reports
Loading...
| Previous Close (in USD) | 18.175 |
|---|---|
| Change | -1.175 6.465% |
| 52 W H/L (in USD) | 35.800/5.800 |
| EBITDA (in USD) | -70.593M |
| PE Ratio | -- |
| Volume | 321857 |
| Diluted Eps TTM | -4.71 |
| Total Assets (in USD) | 82.779M |
|---|---|
| Total Liabilities (in USD) | 21.788M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 76.957M |
| Market Cap (in USD) | 643.520 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Employees: 19
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Paul A. Wagner Ph.D. | CEO & Chairman | 1970 |
| 2. | Mr. Antony A. Riley CPA | Chief Financial Officer | 1967 |
| 3. | Dr. Hubert C. Chen M.D. | Pres & Chief Scientific Officer | 1969 |
| 4. | Mr. Christopher Roenfeldt | Chief Operating Officer | NA |
| 5. | Mr. Steven Ruhl | Chief Technical Officer | 1957 |
| 6. | Dr. Paul A. Wagner Ph.D. | CEO, President & Chairman | 1970 |
| 7. | Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director | 1947 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -68.338M | -35.478M | -31.476M | -13.879M | -21.708M |
| Minority Interest | - | - | - | - | - |
| Net Income | -69.375M | -35.478M | -31.476M | -13.862M | -21.708M |
| Selling General Administrative | 12.41M | 15.409M | 10.624M | 8.302M | 7.633M |
| Gross Profit | -0.064M | -0.039M | -0.009M | - | - |
| Reconciled Depreciation | 0.064M | 0.039M | 0.003M | 0M | 0.036M |
| Ebit | -70.657M | -35.478M | -32.486M | -13.896M | -21.486M |
| Ebitda | -70.593M | -35.439M | -32.477M | -13.896M | -21.45M |
| Depreciation And Amortization | 0.064M | 0.039M | 0.009M | - | 0.036M |
| Operating Income | -70.657M | -36.602M | -32.486M | -13.896M | -21.486M |
| Other Operating Expenses | 70.657M | 36.602M | 32.486M | 13.896M | 21.486M |
| Interest Expense | - | - | - | 0.017M | 0.222M |
| Tax Provision | 1.037M | - | - | - | - |
| Interest Income | 2.715M | 1.314M | 1.124M | - | - |
| Net Interest Income | 2.715M | 1.314M | 1.124M | - | - |
| Income Tax Expense | 1.037M | -35.478M | - | -0.017M | 0.222M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 70.657M | 36.563M | 32.477M | 13.896M | 21.486M |
| Cost Of Revenue | 0.064M | 0.039M | 0.009M | - | - |
| Total Other Income Expense Net | 2.319M | 1.124M | 1.01M | 0.017M | -0.222M |
| Net Income From Continuing Ops | -69.375M | -35.478M | -30.481M | -13.879M | -21.708M |
| Net Income Applicable To Common Shares | - | - | - | -13.879M | -21.708M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 82.779M | 61.561M | 38.98M | 41.997M | 43.306M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.815M | 2.981M | 1.202M | 0.07M | 0.088M |
| Total Liab | 21.788M | 9.081M | 3.666M | 3.179M | 1.758M |
| Total Stockholder Equity | 60.991M | 52.48M | 35.314M | 38.818M | 41.548M |
| Other Current Liab | 9.725M | 4.202M | 2.242M | 2.026M | 0.812M |
| Common Stock | 0.013M | 0.006M | 0.036M | 0.021M | 0.015M |
| Capital Stock | 0.013M | 0.006M | 0.036M | 0.021M | 0.015M |
| Retained Earnings | -223.373M | -153.998M | -118.52M | -87.044M | -73.165M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0M | - | 0.786M |
| Cash | 76.957M | 22.244M | 11.961M | 41.1M | 42.044M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 20.751M | 9.081M | 3.666M | 3.179M | 1.758M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -76.957M | -22.244M | -11.961M | -41.1M | -42.044M |
| Short Term Debt | - | - | - | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | - | - | - | - | - |
| Other Stockholder Equity | 284.348M | 206.461M | 153.794M | 125.841M | 114.698M |
| Property Plant Equipment | - | - | - | - | - |
| Total Current Assets | 80.589M | 61.346M | 38.327M | 41.511M | 42.52M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 36.121M | 25.164M | - | - |
| Net Receivables | 0.817M | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 9.989M | 4.879M | 1.424M | 1.153M | 0.946M |
| Accumulated Other Comprehensive Income | 0.003M | 0.011M | 0.004M | - | -43.306M |
| Non Currrent Assets Other | 2.061M | 0.138M | 0.544M | 0.486M | 0.786M |
| Non Current Assets Total | 2.19M | 0.215M | 0.653M | 0.486M | 0.786M |
| Capital Lease Obligations | - | - | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 36.35M | -35.993M | 0.047M | - | 0M |
| Total Cashflows From Investing Activities | 36.234M | -35.993M | 0.047M | - | - |
| Total Cash From Financing Activities | 69.361M | 51.857M | 24.684M | 7.241M | -0.044M |
| Net Income | -69.375M | -35.478M | -31.476M | -13.879M | -21.708M |
| Change In Cash | 54.713M | -14.881M | -3.975M | -0.944M | -16.721M |
| Begin Period Cash Flow | 22.244M | 37.125M | 41.1M | 42.044M | 58.765M |
| End Period Cash Flow | 76.957M | 22.244M | 37.125M | 41.1M | 42.044M |
| Total Cash From Operating Activities | -50.882M | -30.745M | -28.706M | -8.185M | -16.677M |
| Depreciation | 0.064M | 0.039M | 0.009M | 0M | 0.036M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 0M | -0.001M | -0M | - | - |
| Other Cashflows From Financing Activities | -7.47M | -1.142M | -0.028M | 0.012M | -0.044M |
| Capital Expenditures | 0.116M | 0.037M | 0.088M | 0M | 0.061M |
| Change In Working Capital | 11.371M | 1.757M | -0.392M | 1.679M | 0.72M |
| Other Non Cash Items | -0.237M | -0.158M | -0.131M | - | 0.061M |
| Free Cash Flow | -50.998M | -30.782M | -28.794M | -8.185M | -16.677M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Alger Health Sciences A | 4 months ago | 120918 |
| 2. | Alger LIfe Sciences Innovation Composite | 4 months ago | 86487 |
| 3. | Biotech Growth Ord | 5 months ago | 84995 |
| 4. | Alger Small Cap Growth Institutional I | 4 months ago | 59127 |
| 5. | Alger Small Cap Growth Composite | 4 months ago | 59127 |
| 6. | Fidelity Extended Market Index | 3 months ago | 56214 |
| 7. | Alger 35 ETF | 2 months ago | 38013 |
| 8. | Federated Hermes Kaufmann Growth | 5 months ago | 1040900 |
| 9. | Federated Hermes Kaufmann R | 5 months ago | 1040900 |
| 10. | Federated Hermes Kaufmann Small Cap Grow | 5 months ago | 702400 |
| 11. | Federated Hermes Kaufmann Small Cap A | 5 months ago | 702400 |
| 12. | Alger Small Cap Focus Composite | 4 months ago | 496062 |
| 13. | Alger Small Cap Focus I | 4 months ago | 496062 |
| 14. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 393727 |
| 15. | Fidelity Select Biotechnology | 3 months ago | 310965 |
| 16. | Alger Small Cap Growth B | 4 months ago | 157755 |
| 17. | Alger Large Cap Growth Composite | 4 months ago | 139472 |
| 18. | Alger Large Cap Growth I-2 | 4 months ago | 139472 |
| 19. | Alger Small Cap Growth I-2 | 4 months ago | 128020 |
| 20. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 124882 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Federated Hermes Inc | 8 months ago | 1635380 |
| 2. | Fred Alger Management, LLC | 5 months ago | 1460971 |
| 3. | HHG PLC | 8 months ago | 1403842 |
| 4. | Orbimed Advisors, LLC | 5 months ago | 1196955 |
| 5. | Affinity Asset Advisors, LLC | 5 months ago | 989490 |
| 6. | Tybourne Capital Management (HK) Ltd | 8 months ago | 786647 |
| 7. | Vanguard Group Inc | 5 months ago | 582263 |
| 8. | Point72 Asset Management, L.P. | 5 months ago | 487275 |
| 9. | Cable Car Capital LLC | 5 months ago | 400000 |
| 10. | Adage Capital Partners Gp LLC | 5 months ago | 333333 |
| 11. | Woodline Partners LP | 5 months ago | 331987 |
| 12. | FMR Inc | 5 months ago | 310965 |
| 13. | Ikarian Capital, LLC | 5 months ago | 300000 |
| 14. | Millennium Management LLC | 5 months ago | 246685 |
| 15. | Awm Investment Company Inc | 5 months ago | 236821 |
| 16. | Jain Global LLC | 5 months ago | 202433 |
| 17. | Sphera Funds Management Ltd. | 5 months ago | 185869 |
| 18. | Geode Capital Management, LLC | 5 months ago | 124609 |
| 19. | Ameriprise Financial Inc | 8 months ago | 69892 |
| 20. | The Goldman Sachs Group Inc | 5 months ago | 68023 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...